Your browser doesn't support javascript.
loading
Arterial hypertension and ß-amyloid accumulation have spatially overlapping effects on posterior white matter hyperintensity volume: a cross-sectional study.
Bernal, Jose; Schreiber, Stefanie; Menze, Inga; Ostendorf, Anna; Pfister, Malte; Geisendörfer, Jonas; Nemali, Aditya; Maass, Anne; Yakupov, Renat; Peters, Oliver; Preis, Lukas; Schneider, Luisa; Herrera, Ana Lucia; Priller, Josef; Spruth, Eike Jakob; Altenstein, Slawek; Schneider, Anja; Fliessbach, Klaus; Wiltfang, Jens; Schott, Björn H; Rostamzadeh, Ayda; Glanz, Wenzel; Buerger, Katharina; Janowitz, Daniel; Ewers, Michael; Perneczky, Robert; Rauchmann, Boris-Stephan; Teipel, Stefan; Kilimann, Ingo; Laske, Christoph; Munk, Matthias H; Spottke, Annika; Roy, Nina; Dobisch, Laura; Dechent, Peter; Scheffler, Klaus; Hetzer, Stefan; Wolfsgruber, Steffen; Kleineidam, Luca; Schmid, Matthias; Berger, Moritz; Jessen, Frank; Wirth, Miranka; Düzel, Emrah; Ziegler, Gabriel.
Affiliation
  • Bernal J; Institute of Cognitive Neurology and Dementia Research, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany. jose.bernalmoyano@dzne.de.
  • Schreiber S; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany. jose.bernalmoyano@dzne.de.
  • Menze I; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
  • Ostendorf A; Department of Neurology, Medical Faculty, University Hospital Magdeburg, Magdeburg, Germany.
  • Pfister M; Institute of Cognitive Neurology and Dementia Research, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany.
  • Geisendörfer J; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
  • Nemali A; Institute of Cognitive Neurology and Dementia Research, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany.
  • Maass A; Department of Neurology, Medical Faculty, University Hospital Magdeburg, Magdeburg, Germany.
  • Yakupov R; Department of Neurology, Medical Faculty, University Hospital Magdeburg, Magdeburg, Germany.
  • Peters O; Institute of Cognitive Neurology and Dementia Research, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany.
  • Preis L; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
  • Schneider L; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
  • Herrera AL; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
  • Priller J; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
  • Spruth EJ; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität Zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany.
  • Altenstein S; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität Zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany.
  • Schneider A; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität Zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany.
  • Fliessbach K; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität Zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany.
  • Wiltfang J; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
  • Schott BH; Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Rostamzadeh A; School of Medicine, Department of Psychiatry and Psychotherapy, Technical University of Munich, Munich, Germany.
  • Glanz W; University of Edinburgh and UK DRI, Edinburgh, UK.
  • Buerger K; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
  • Janowitz D; Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Ewers M; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
  • Perneczky R; Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Rauchmann BS; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Teipel S; Clinic for Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn, Bonn, Germany.
  • Kilimann I; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Laske C; Clinic for Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn, Bonn, Germany.
  • Munk MH; German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany.
  • Spottke A; Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Goettingen, Germany.
  • Roy N; Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal.
  • Dobisch L; German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany.
  • Dechent P; Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Goettingen, Germany.
  • Scheffler K; Department of Psychiatry, University of Cologne, Cologne, Germany.
  • Hetzer S; Institute of Cognitive Neurology and Dementia Research, Otto-Von-Guericke University Magdeburg, Magdeburg, Germany.
  • Wolfsgruber S; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
  • Kleineidam L; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
  • Schmid M; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
  • Berger M; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
  • Jessen F; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
  • Wirth M; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
  • Düzel E; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.
  • Ziegler G; Munich Cluster for Systems Neurology (SyNergy) Munich, Munich, Germany.
Alzheimers Res Ther ; 15(1): 97, 2023 05 24.
Article in En | MEDLINE | ID: mdl-37226207
ABSTRACT

BACKGROUND:

White matter hyperintensities (WMH) in subjects across the Alzheimer's disease (AD) spectrum with minimal vascular pathology suggests that amyloid pathology-not just arterial hypertension-impacts WMH, which in turn adversely influences cognition. Here we seek to determine the effect of both hypertension and Aß positivity on WMH, and their impact on cognition.

METHODS:

We analysed data from subjects with a low vascular profile and normal cognition (NC), subjective cognitive decline (SCD), and amnestic mild cognitive impairment (MCI) enrolled in the ongoing observational multicentre DZNE Longitudinal Cognitive Impairment and Dementia Study (n = 375, median age 70.0 [IQR 66.0, 74.4] years; 178 female; NC/SCD/MCI 127/162/86). All subjects underwent a rich neuropsychological assessment. We focused on baseline memory and executive function-derived from multiple neuropsychological tests using confirmatory factor analysis-, baseline preclinical Alzheimer's cognitive composite 5 (PACC5) scores, and changes in PACC5 scores over the course of three years (ΔPACC5).

RESULTS:

Subjects with hypertension or Aß positivity presented the largest WMH volumes (pFDR < 0.05), with spatial overlap in the frontal (hypertension 0.42 ± 0.17; Aß 0.46 ± 0.18), occipital (hypertension 0.50 ± 0.16; Aß 0.50 ± 0.16), parietal lobes (hypertension 0.57 ± 0.18; Aß 0.56 ± 0.20), corona radiata (hypertension 0.45 ± 0.17; Aß 0.40 ± 0.13), optic radiation (hypertension 0.39 ± 0.18; Aß 0.74 ± 0.19), and splenium of the corpus callosum (hypertension 0.36 ± 0.12; Aß 0.28 ± 0.12). Elevated global and regional WMH volumes coincided with worse cognitive performance at baseline and over 3 years (pFDR < 0.05). Aß positivity was negatively associated with cognitive performance (direct effect-memory - 0.33 ± 0.08, pFDR < 0.001; executive - 0.21 ± 0.08, pFDR < 0.001; PACC5 - 0.29 ± 0.09, pFDR = 0.006; ΔPACC5 - 0.34 ± 0.04, pFDR < 0.05). Splenial WMH mediated the relationship between hypertension and cognitive performance (indirect-only effect-memory - 0.05 ± 0.02, pFDR = 0.029; executive - 0.04 ± 0.02, pFDR = 0.067; PACC5 - 0.05 ± 0.02, pFDR = 0.030; ΔPACC5 - 0.09 ± 0.03, pFDR = 0.043) and WMH in the optic radiation partially mediated that between Aß positivity and memory (indirect effect-memory - 0.05 ± 0.02, pFDR = 0.029).

CONCLUSIONS:

Posterior white matter is susceptible to hypertension and Aß accumulation. Posterior WMH mediate the association between these pathologies and cognitive dysfunction, making them a promising target to tackle the downstream damage related to the potentially interacting and potentiating effects of the two pathologies. TRIAL REGISTRATION German Clinical Trials Register (DRKS00007966, 04/05/2015).
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease / White Matter / Hypertension Type of study: Observational_studies / Prevalence_studies / Risk_factors_studies Limits: Aged / Female / Humans Language: En Journal: Alzheimers Res Ther Year: 2023 Type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease / White Matter / Hypertension Type of study: Observational_studies / Prevalence_studies / Risk_factors_studies Limits: Aged / Female / Humans Language: En Journal: Alzheimers Res Ther Year: 2023 Type: Article Affiliation country: Germany